Beneficial impact of Baricitinib in COVID-19 moderate pneumonia; multicentre study

doi:10.1016/j.jinf.2020.06.052

Comment

. 2020 Oct;81(4):647-679.

doi: 10.1016/j.jinf.2020.06.052. Epub 2020 Jun 24.

Beneficial impact of Baricitinib in COVID-19 moderate pneumonia; multicentre study

Fabrizio Cantini¹, Laura Niccoli², Carlotta Nannini², Daniela Matarrese³, Massimo Edoardo Di Natale⁴, Pamela Lotti⁵, Donatella Aquilini⁶, Giancarlo Landini⁷, Barbara Cimolato⁸, Massimo Antonio Di Pietro⁹, Michele Trezzi¹⁰, Paolo Stobbione¹¹, Gabriele Frausini¹², Assunta Navarra¹³, Emanuele Nicastri¹⁴, Giovanni Sotgiu¹⁵, Delia Goletti¹⁶

Affiliations

¹ Rheumatology department, Azienda USL Toscana Centro, Hospital of Prato, Italy. Electronic address: fbrzcantini@gmail.com.
² Rheumatology department, Azienda USL Toscana Centro, Hospital of Prato, Italy.
³ Sanitary Direction, Azienda USL Toscana Centro, Hospital of Prato, Italy. Electronic address: daniela.matarrese@uslcentro.toscana.it.
⁴ II Division of Internal Medicine, Azienda USL Toscana Centro, Hospital of Prato, Italy. Electronic address: massimoedoardo.dinatale@uslcentro.toscana.it.
⁵ II Division of Internal Medicine, Azienda USL Toscana Centro, Hospital of Prato, Italy. Electronic address: pamela.lotti@uslcentro.toscana.it.
⁶ Division of Infectious Diseases, Azienda USL Toscana Centro, Hospital of Prato, Italy. Electronic address: donatella.aquilini@uslcentro.toscana.it.
⁷ Department of Medical Specialties, Division of Internal Medicine, Azienda USL Toscana Centro, S.Maria Nuova Hospital, Florence, Italy. Electronic address: giancarlo.landini@uslcentro.toscana.it.
⁸ Department of Medical Specialties, Division of Internal Medicine, Azienda USL Toscana Centro, S.Maria Nuova Hospital, Florence, Italy. Electronic address: barbara.cimolato@uslcentro.toscana.it.
⁹ Division of Infectious Diseases, Azienda USL Toscana Centro, Hospital of Pistoia, Italy. Electronic address: massimoantonio.dipietro@uslcentro.toscana.it.
¹⁰ Division of Infectious Diseases, Azienda USL Toscana Centro, Hospital of Pistoia, Italy. Electronic address: michele.trezzi@uslcentro.toscana.it.
¹¹ Rheumatology Unit, AO SS. Antonio e Biagio e C. Arrigo, Alessandria, Italy. Electronic address: pstobbione@ospedale.al.it.
¹² Division of Internal Medicine, Azienda Ospedaliera Ospedali Riuniti Marche Nord, Fano-Pesaro, Italy. Electronic address: gabriele.frausini@ospedalimarchenord.it.
¹³ Clinical epidemiology Unit, National Institute for Infectious Diseases, Lazzaro Spallanzani, Rome, Italy. Electronic address: assunta.navarra@inmi.it.
¹⁴ Clinical Division of Infectious Diseases, National Institute for Infectious Diseases, Lazzaro Spallanzani, IRCCS, Rome, Italy. Electronic address: emanuele.nicastri@inmi.it.
¹⁵ Clinical Epidemiology and Medical Statistics Unit, Department of Medical, Surgical and Experimental Sciences, University of Sassari, Sassari, Italy. Electronic address: gsotgiu@uniss.it.
¹⁶ Translational Research Unit, Department of Epidemiology and Preclinical Research, "L. Spallanzani" National Institute for Infectious Diseases (INMI), IRCCS, Rome, Italy. Electronic address: delia.goletti@inmi.it.

PMID: 32592703
PMCID: PMC7313480
DOI: 10.1016/j.jinf.2020.06.052

Comment

Beneficial impact of Baricitinib in COVID-19 moderate pneumonia; multicentre study

Fabrizio Cantini et al. J Infect. 2020 Oct.

. 2020 Oct;81(4):647-679.

doi: 10.1016/j.jinf.2020.06.052. Epub 2020 Jun 24.

Authors

Affiliations

¹ Rheumatology department, Azienda USL Toscana Centro, Hospital of Prato, Italy. Electronic address: fbrzcantini@gmail.com.
² Rheumatology department, Azienda USL Toscana Centro, Hospital of Prato, Italy.
³ Sanitary Direction, Azienda USL Toscana Centro, Hospital of Prato, Italy. Electronic address: daniela.matarrese@uslcentro.toscana.it.
⁴ II Division of Internal Medicine, Azienda USL Toscana Centro, Hospital of Prato, Italy. Electronic address: massimoedoardo.dinatale@uslcentro.toscana.it.
⁵ II Division of Internal Medicine, Azienda USL Toscana Centro, Hospital of Prato, Italy. Electronic address: pamela.lotti@uslcentro.toscana.it.
⁶ Division of Infectious Diseases, Azienda USL Toscana Centro, Hospital of Prato, Italy. Electronic address: donatella.aquilini@uslcentro.toscana.it.
⁷ Department of Medical Specialties, Division of Internal Medicine, Azienda USL Toscana Centro, S.Maria Nuova Hospital, Florence, Italy. Electronic address: giancarlo.landini@uslcentro.toscana.it.
⁸ Department of Medical Specialties, Division of Internal Medicine, Azienda USL Toscana Centro, S.Maria Nuova Hospital, Florence, Italy. Electronic address: barbara.cimolato@uslcentro.toscana.it.
⁹ Division of Infectious Diseases, Azienda USL Toscana Centro, Hospital of Pistoia, Italy. Electronic address: massimoantonio.dipietro@uslcentro.toscana.it.
¹⁰ Division of Infectious Diseases, Azienda USL Toscana Centro, Hospital of Pistoia, Italy. Electronic address: michele.trezzi@uslcentro.toscana.it.
¹¹ Rheumatology Unit, AO SS. Antonio e Biagio e C. Arrigo, Alessandria, Italy. Electronic address: pstobbione@ospedale.al.it.
¹² Division of Internal Medicine, Azienda Ospedaliera Ospedali Riuniti Marche Nord, Fano-Pesaro, Italy. Electronic address: gabriele.frausini@ospedalimarchenord.it.
¹³ Clinical epidemiology Unit, National Institute for Infectious Diseases, Lazzaro Spallanzani, Rome, Italy. Electronic address: assunta.navarra@inmi.it.
¹⁴ Clinical Division of Infectious Diseases, National Institute for Infectious Diseases, Lazzaro Spallanzani, IRCCS, Rome, Italy. Electronic address: emanuele.nicastri@inmi.it.
¹⁵ Clinical Epidemiology and Medical Statistics Unit, Department of Medical, Surgical and Experimental Sciences, University of Sassari, Sassari, Italy. Electronic address: gsotgiu@uniss.it.
¹⁶ Translational Research Unit, Department of Epidemiology and Preclinical Research, "L. Spallanzani" National Institute for Infectious Diseases (INMI), IRCCS, Rome, Italy. Electronic address: delia.goletti@inmi.it.

PMID: 32592703
PMCID: PMC7313480
DOI: 10.1016/j.jinf.2020.06.052

Abstract

•
Baricitinib, an anti-JAK1/JAK2, reduces cytokine release and SARS-Co-V2 entry.
•
In a retrospective multicenter study baricitinib reduces COVID-19 mortality rate.
•
Baricitinib reduces intensive care unit admissions of COVID-19 pneumonia.
•
Baricitinb reduces SARS-CoV-2 viral burden detected by nasopharyngeal swab.
•
Baricitinib used for 2 weeks was not associated with serious adverse events.

Keywords: Baricitinib; COVID-19; JAK1/2; Pneumonia; Retrospective study; SARS-Co-V2.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest All Authors have nothing to disclose.

Figures

Image, graphical abstract — **Graphical abstract**

See this image and copyright information in PMC

Comment on

Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact.
Cantini F, Niccoli L, Matarrese D, Nicastri E, Stobbione P, Goletti D. Cantini F, et al. J Infect. 2020 Aug;81(2):318-356. doi: 10.1016/j.jinf.2020.04.017. Epub 2020 Apr 23. J Infect. 2020. PMID: 32333918 Free PMC article.

Cited by

Therapeutic strategies to fight COVID-19: Which is the status artis?
Scavone C, Mascolo A, Rafaniello C, Sportiello L, Trama U, Zoccoli A, Bernardi FF, Racagni G, Berrino L, Castaldo G, Coscioni E, Rossi F, Capuano A. Scavone C, et al. Br J Pharmacol. 2022 May;179(10):2128-2148. doi: 10.1111/bph.15452. Epub 2021 May 7. Br J Pharmacol. 2022. PMID: 33960398 Free PMC article. Review.
Evidence-based management of COVID-19 in cancer patients: Guideline by the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO).
Giesen N, Sprute R, Rüthrich M, Khodamoradi Y, Mellinghoff SC, Beutel G, Lueck C, Koldehoff M, Hentrich M, Sandherr M, von Bergwelt-Baildon M, Wolf HH, Hirsch HH, Wörmann B, Cornely OA, Köhler P, Schalk E, von Lilienfeld-Toal M. Giesen N, et al. Eur J Cancer. 2020 Nov;140:86-104. doi: 10.1016/j.ejca.2020.09.009. Epub 2020 Sep 21. Eur J Cancer. 2020. PMID: 33068941 Free PMC article.
Jakinibs of All Trades: Inhibiting Cytokine Signaling in Immune-Mediated Pathologies.
Alexander M, Luo Y, Raimondi G, O'Shea JJ, Gadina M. Alexander M, et al. Pharmaceuticals (Basel). 2021 Dec 30;15(1):48. doi: 10.3390/ph15010048. Pharmaceuticals (Basel). 2021. PMID: 35056105 Free PMC article. Review.
COVID-19, cytokines, inflammation, and spices: How are they related?
Kunnumakkara AB, Rana V, Parama D, Banik K, Girisa S, Henamayee S, Thakur KK, Dutta U, Garodia P, Gupta SC, Aggarwal BB. Kunnumakkara AB, et al. Life Sci. 2021 Nov 1;284:119201. doi: 10.1016/j.lfs.2021.119201. Epub 2021 Feb 16. Life Sci. 2021. PMID: 33607159 Free PMC article. Review.
Activation of the SARS-CoV-2 Receptor Ace2 through JAK/STAT-Dependent Enhancers during Pregnancy.
Hennighausen L, Lee HK. Hennighausen L, et al. Cell Rep. 2020 Sep 29;32(13):108199. doi: 10.1016/j.celrep.2020.108199. Epub 2020 Sep 6. Cell Rep. 2020. PMID: 32966801 Free PMC article.

See all "Cited by" articles

References

1. Cantini F., Niccoli L., Matarrese D., Nicastri E., Stobbione P., Goletti D. Baricitinib therapy in COVID-19: a pilot study on safety and clinical impact. J Infect. 2020 doi: 10.1016/j.jinf.2020.04.017. Apr 23Epub ahead of print] - DOI - PMC - PubMed
1. Huang C., Wang Y., Li X., Ren L., Zhao J., Hu Y. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. - PMC - PubMed
1. Sun X., Wang T., Cai D. Cytokine storm intervention in the early stages of COVID-19 pneumonia. Cytokine Growth Factor Rev. 2020 doi: 10.1016/j.cytogfr.2020.04.002. Apr. 25. - DOI - PMC - PubMed
1. Adachi T., Chong J.M., Nakajima N. Clinicopathological and immunohistochemical findings from autopsy of patient with COVID-19, Japan. Emerg Infect Dis. 2020;26(9) doi: 10.3201/eid2609.201353. May 15[Epub ahead of print] - DOI - PMC - PubMed
1. Stebbing J., Phelan A., Griffin I., Tucker C., Oechsle O., Richardson P. COVID-19: combining antiviral and anti-inflammatory treatments. Lancet Infect Dis 2020. 2020 doi: 10.1016/51473-3099(20)30132-8. Published online February 27https//doi.org/ - DOI - PMC - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
Other Literature Sources
- The Lens - Patent Citations Database
Research Materials
- NCI CPTC Antibody Characterization Program
Miscellaneous
- NCI CPTAC Assay Portal

[1] Cantini F., Niccoli L., Matarrese D., Nicastri E., Stobbione P., Goletti D. Baricitinib therapy in COVID-19: a pilot study on safety and clinical impact. J Infect. 2020 doi: 10.1016/j.jinf.2020.04.017. Apr 23Epub ahead of print] - DOI - PMC - PubMed

[2] Cantini F., Niccoli L., Matarrese D., Nicastri E., Stobbione P., Goletti D. Baricitinib therapy in COVID-19: a pilot study on safety and clinical impact. J Infect. 2020 doi: 10.1016/j.jinf.2020.04.017. Apr 23Epub ahead of print] - DOI - PMC - PubMed

[3] Huang C., Wang Y., Li X., Ren L., Zhao J., Hu Y. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. - PMC - PubMed

[4] Huang C., Wang Y., Li X., Ren L., Zhao J., Hu Y. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. - PMC - PubMed

[5] Sun X., Wang T., Cai D. Cytokine storm intervention in the early stages of COVID-19 pneumonia. Cytokine Growth Factor Rev. 2020 doi: 10.1016/j.cytogfr.2020.04.002. Apr. 25. - DOI - PMC - PubMed

[6] Sun X., Wang T., Cai D. Cytokine storm intervention in the early stages of COVID-19 pneumonia. Cytokine Growth Factor Rev. 2020 doi: 10.1016/j.cytogfr.2020.04.002. Apr. 25. - DOI - PMC - PubMed

[7] Adachi T., Chong J.M., Nakajima N. Clinicopathological and immunohistochemical findings from autopsy of patient with COVID-19, Japan. Emerg Infect Dis. 2020;26(9) doi: 10.3201/eid2609.201353. May 15[Epub ahead of print] - DOI - PMC - PubMed

[8] Adachi T., Chong J.M., Nakajima N. Clinicopathological and immunohistochemical findings from autopsy of patient with COVID-19, Japan. Emerg Infect Dis. 2020;26(9) doi: 10.3201/eid2609.201353. May 15[Epub ahead of print] - DOI - PMC - PubMed

[9] Stebbing J., Phelan A., Griffin I., Tucker C., Oechsle O., Richardson P. COVID-19: combining antiviral and anti-inflammatory treatments. Lancet Infect Dis 2020. 2020 doi: 10.1016/51473-3099(20)30132-8. Published online February 27https//doi.org/ - DOI - PMC - PubMed

[10] Stebbing J., Phelan A., Griffin I., Tucker C., Oechsle O., Richardson P. COVID-19: combining antiviral and anti-inflammatory treatments. Lancet Infect Dis 2020. 2020 doi: 10.1016/51473-3099(20)30132-8. Published online February 27https//doi.org/ - DOI - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Beneficial impact of Baricitinib in COVID-19 moderate pneumonia; multicentre study

Affiliations

Beneficial impact of Baricitinib in COVID-19 moderate pneumonia; multicentre study

Authors

Affiliations

Abstract

Conflict of interest statement

Figures

Comment on

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Research Materials

Miscellaneous

Abstract

Conflict of interest statement

Figures

Comment on

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Related information

LinkOut - more resources

Full Text Sources

Other Literature Sources

Research Materials

Miscellaneous